Model-Based Determination of Elotuzumab Pharmacokinetics in Japanese Patients With Multiple Myeloma Incorporating Time-Varying M Protein.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ pharmacokinetics
Antineoplastic Agents
/ pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Asian People
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Glomerular Filtration Rate
Humans
Japan
Male
Metabolic Clearance Rate
Middle Aged
Models, Biological
Multiple Myeloma
/ drug therapy
Myeloma Proteins
/ metabolism
Japanese
monoclonal antibody
multiple myeloma
population pharmacokinetics
target-mediated drug disposition
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
22
04
2020
accepted:
21
06
2020
pubmed:
14
7
2020
medline:
15
12
2021
entrez:
14
7
2020
Statut:
ppublish
Résumé
A population pharmacokinetic model was developed to evaluate the effects of Japanese ethnicity, prior line of therapy (0 or ≥1), time-varying M protein, and maintenance dosing regimens (10 mg/kg intravenously every 2 weeks or 20 mg/kg intravenously every 4 weeks beginning in cycle 19) on the pharmacokinetics of elotuzumab in patients with multiple myeloma treated with elotuzumab plus lenalidomide/dexamethasone. Elotuzumab pharmacokinetics were characterized by a 2-compartment model with parallel linear (nonspecific) and Michaelis-Menten elimination from the central compartment and target-mediated elimination from the peripheral compartment. Asian race on nonspecific clearance (CL) and central volume of distribution, prior line of therapy on CL, and maximum target-mediated elimination rate (V
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
Myeloma Proteins
0
multiple myeloma M-proteins
0
elotuzumab
1351PE5UGS
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
64-73Informations de copyright
© 2020, The American College of Clinical Pharmacology.
Références
Bristol-Myers Squibb. Empliciti (elotuzumab) prescribing information. 2018. http://packageinserts.bms.com/pi/pi_empliciti.pdf. Accessed February 24, 2020.
Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775-2784.
Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329-1337.
Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841-1849.
Balasa B, Yun R, Belmar NA, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways. Cancer Immunol Immunother. 2015;64(1):61-73.
Pazina T, James AM, MacFarlane AW, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology. 2017;6(9):e1339853.
Kurdi AT, Glavey SV, Bezman NA, et al. Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Mol Cancer Ther. 2018;17(7):1454-1463.
Takezako N, Ohta K, Handa H, et al. Elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in patients with newly diagnosed multiple myeloma: phase 2, randomized, open-label study in Japan. Blood. 2017;130(suppl 1):434-434.
Gibiansky L, Passey C, Roy A, Bello A, Gupta M. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma. J Pharmacokinet Pharmacodyn. 2016;43(3):243-257.
Passey C, Mora J, Dodge R, et al. An integrated assessment of the effects of immunogenicity on the pharmacokinetics, safety, and efficacy of elotuzumab. AAPS J. 2016;19(2):557-567.
Ramalingam SS, Kummar S, Sarantopoulos J, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol. 2010;28(29):4507-4512.
Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12(1):42-54.
Iida S, Nagai H, Kinoshita G, et al. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: Phase 1 study. Int J Hematol. 2017;105(3):326-334.
Bristol-Myers Squibb. Japanese study of BMS-901608 (elotuzumab) in combination with lenalidomide and low dose dexamethasone. 2018. https://clinicaltrials.gov/ct2/show/NCT01241292. Accessed February 13, 2020.
Bristol-Myers Squibb. Study of elotuzumab in combination with lenalidomide and dexamethasone in subjects with multiple myeloma and various levels of renal function. 2017. https://clinicaltrials.gov/ct2/show/NCT01393964. Accessed February 13, 2020.
Bristol-Myers Squibb. Biomarker study of elotuzumab in high risk smoldering myeloma. 2018. https://clinicaltrials.gov/ct2/show/NCT01441973. Accessed February 13, 2020.
Bristol-Myers Squibb. Phase II study of lenalidomide/dexamethasone with or without elotuzumab for newly diagnosed MM patients in Japan. 2018. https://clinicaltrials.gov/ct2/show/NCT02272803. Accessed February 13, 2020.
Bristol-Myers Squibb. Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat relapsed or refractory multiple myeloma (ELOQUENT-2). 2018. https://clinicaltrials.gov/ct2/show/NCT01239797. Accessed February 13, 2020.
Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621-631.
Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ. NONMEM Users Guides. Hanover, Maryland: Icon Development Solutions; 2015:1989-2011.
Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143-151.
Xu XS, Liao S, Dimopoulos MA, et al. Population pharmacokinetic and exposure-response analyses for daratumumab in combination therapies for patients with multiple myeloma who have received 1 or more prior lines of therapy. Blood. 2016;128(22):3340-3340.
Chiba K, Yoshitsugu H, Kyosaka Y, et al. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed? J Clin Pharmacol. 2014;54(5):483-494.
Matsushima S, Huang Y, Suzuki H, Nishino J, Lloyd P. Ethnic sensitivity assessment - pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs. Expert Opin Drug Metab Toxicol. 2015;11(2):179-191.
Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633-659.
AbbVie Inc. HUMIRA (adalimumab) Prescribing Information. 2019. AbbVie Inc. http://www.rxabbvie.com/pdf/humira.pdf. Accessed February 13, 2020.
Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-216.